Testing pain killers on humans could save money and speed the arrival of new drugs

November 8, 2012

Deliberately inflicting carefully controlled painful stimuli on human volunteers and seeing how well specific drugs reduce the feeling of pain can be an effective way of testing new drugs. So conclude two researchers who reviewed the available literature on these types of tests in a paper published in the British Journal of Pharmacology.

Pain is important. It acts as an alarm mechanism, warning us that something is about to cause physical damage. It could be triggered by something physical like a cut or bruise, or a temperature driven such as or cold. It could be caused internally by injuries where nerves get trapped. Pain can also become a long-term sensation that lasts long after the damage has occurred. In this case it is referred to as 'chronic' pain, and this can be particularly hard to treat.

The need to tackle pain is huge. A fifth of suffer from daily pain requiring treatment, with the proportion increasing in people over 70 years old. But pain control is still often insufficient or unsatisfactory because the available drugs fail to provide adequate relief or produce major side effects. Pain has therefore remained one of the major healthcare problems generating estimated socio- of $560-635 billion/year in the USA alone.

Finding new drugs is complicated because you can't measure pain directly. In animal models you have to watch animals as they respond to stimuli, and in human trials you have to get individuals to report how they feel. On top of this, the body has a number of different ways of detecting pain- generating stimuli, and each mechanism is likely to respond to a different set of pain-killing drugs.

Based in Frankfurt am Main, Germany, Bruno Georg Oertel and Jörn Lötsch started out with a theory. "We thought that if a pain-relieving drug was effective in a particular experimental pain model and also in a specific type of clinical pain, then the should be predictive for the particular clinical setting," says Lötsch, who works in the Institute of Clinical Pharmacology at the Goethe-University.

They found that overall, human experimental pain models were able to predict how well a drug worked in patients better than previously realised. "Not using these pain models in seems to be unjustified – in fact they should be used routinely in drug development programmes," says Oertel, who works in the Fraunhofer Project Group for Translational Medicine and Pharmacology (TMP), an initiative supported by the Hessian Excellence Initiative ("LOEWE") that runs at the junction between pharmacological research in academia and in the pharmaceutical industry.

The process isn't simple though as not every model can predict every clinical setting. "However, by analysing the way that drugs work in experimental and clinical settings, we identified that different sets of experimental pain models, rather than single models, may be best suited to provide cost-effective yet predictive studies in analgesic drug development," says Lötsch.

"It is difficult and unusual to undertake truly translational research in pharmacology. Here, Jörn Lötsch and Bruno G. Oertel have focused on experiments on humans to bridge the gap between animal research and clinical pharmacology. The review examines how well clinical analgesia is predicted by human experimental pain models, with a view to guiding model selection in phase I studies. The authors identify important disparities between drug effects on experimental and clinical pain. This will help inform thinking on the refinement of human and animal models of pain, ultimately helping the pharmaceutical industry bridge the translational gap in the field," says Editor-in-Chief of the British Journal of Pharmacology, Professor Ian McGrath.

More work is needed before this approach is fully ready to use, but the researchers believe this could lead to a more cost effective approach that can help scientists gain valuable information about the ways are working.

Explore further: New insight into pain mechanisms

More information: Bruno Georg Oertel and Jörn Lötsch; Clinical pharmacology of analgesics assessed with human experimental pain models: Bridging basic and clinical research; British Journal of Pharmacology 2012; DOI: 10.1111/bph.12023

Related Stories

New insight into pain mechanisms

April 25, 2012
(Medical Xpress) -- Researchers in the UCL Wolfson Institute for Biomedical Research have made a discovery which could help the development of analgesic drugs able to treat nerve damage-related pain.

Designing a new drug for chronic pain

August 24, 2012
(Medical Xpress)—Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded £1.4 million to design a new drug for the treatment of chronic pain.

Pain relief can now be based on solid evidence

September 7, 2011
A Cochrane Review of data relating to about 45,000 patients involved in approximately 350 individual studies has provided an evaluation of the effect you can expect to get if you take commonly used painkillers at specific ...

Chronic pain gene identified

September 8, 2011
British researchers say they have identified the gene that controls chronic pain, opening the door to new drug therapies that block the chemical processes that cause chronic back pain, headaches or arthritis.

Heroin addicts have higher pain sensitivity, even during treatment

April 25, 2012
(HealthDay) -- Heroin addicts often have an increased sensitivity to pain, and this sensitivity does not subside over the course of treatment with methadone or other opioids, new research finds.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.